[1] |
WEN Ziqiang, LAN Junliang, ZHOU Bo, XU Qiwei.
PARP1 promotes the progression of hepatocellular carcinoma by regulating expression of POU2F2
[J]. China Oncology, 2024, 34(9): 848-856.
|
[2] |
XIAO Feng, XU Tonglin, ZHU Lin, XIAO Jingwen, WU Tianqi, GU Chunyan.
Significance of infiltration of M1 tumor-associated macrophages in hepatocellular carcinoma
[J]. China Oncology, 2024, 34(8): 726-733.
|
[3] |
LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan.
Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications
[J]. China Oncology, 2024, 34(4): 368-379.
|
[4] |
China Anti-Cancer Association Tumor Biomarker Professional Committee, Shanghai Anti-Cancer Association Tumor Biomarker Professional Committee.
Expert consensus on population-based BRCA germline mutation screening in China (2024 edition)
[J]. China Oncology, 2024, 34(2): 220-238.
|
[5] |
LI Jun, LU Tingwei, FANG Xuqian.
Impact of MSI-H/dMMR on clinicopathological characteristics and prognosis of patients with BRAF V600E-mutated resectable colorectal cancer
[J]. China Oncology, 2024, 34(11): 1061-1066.
|
[6] |
ZHAO Haichao, GAO Qiang.
Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022
[J]. China Oncology, 2023, 33(4): 315-326.
|
[7] |
ZHAO Bolun, ZHU Guannan.
Advances in the treatment of advanced melanoma with NRAS gene mutation
[J]. China Oncology, 2023, 33(10): 936-944.
|
[8] |
HU Keshu, LIU Wenfeng, ZHANG Feng, QUAN Bing, YIN Xin.
Mechanism of LINC00601 in regulating sensitivity of hepatocellular carcinoma cells to oxaliplatin chemotherapy
[J]. China Oncology, 2023, 33(1): 25-35.
|
[9] |
HE Liyuan, WANG Yudong.
Research progress of ALK kinase domain drug resistance mutation and its future countermeasures
[J]. China Oncology, 2022, 32(8): 736-746.
|
[10] |
DENG Shuting, FENG Yuan, QIAN Kai, GUO Kai, WANG Zhuoying.
Meta-analysis of the association between gene alterations and distant metastasis of differentiated thyroid carcinoma in children and adolescents
[J]. China Oncology, 2022, 32(5): 388-396.
|
[11] |
JIANG Jianyun, YING Hongmei.
Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma
[J]. China Oncology, 2022, 32(5): 445-450.
|
[12] |
LI Ting, XU Yu, JIA Dongdong, LIAO Zhichao, SUN Wei, WU Haixiao, REN Zhiwu, ZHAO Jun, XING Ruwei, TENG Sheng, YANG Yun, CHEN Yong, LI Tao, YANG Jilong.
Adjuvant therapy with anti-PD-1 antibody vs targeted therapy for patients with resected stage Ⅲ malignant melanoma: a real-world data analysis from China centers
[J]. China Oncology, 2022, 32(12): 1147-1157.
|
[13] |
SHI Yue, CHEN Yiqing, DING Jingxin, NING Yan, WANG Qing, MA Fenghua, TAN Haowen, KANG Yu.
Questionnaire survey on current status of clinical screening and treatment of gynecological disease in females with Peutz-Jeghers syndrome
[J]. China Oncology, 2022, 32(11): 1049-1064.
|
[14] |
CHENG Yicai, DU Zhenhua, FAN Zhijuan, FENG Lan, CAO Pengbo, ZHOU Gangqiao.
Plasma exosomal CD48 protein as a candidate diagnostic biomarker for hepatocellular carcinoma
[J]. China Oncology, 2022, 32(11): 1074-1083.
|
[15] |
GUO Tao, SONG Ning, SUN Yuqi, TIAN Jiaqi, TANG Jie, SUN Rongqi, JIANG Yingying.
Effect of long non-coding RNA LINC00671 on biological behavior of hepatocellular carcinoma and its mechanism
[J]. China Oncology, 2022, 32(10): 990-999.
|